Pharma BD Deal Intelligence
Novavax announces ~$167 million all-cash acquisition of Praha Vaccines, adding a Czech manufacturing facility to reach more than one billion doses of antigen…
"The Praha acquisition gives Novavax the chance to manufacture its vaccine on a similar scale" to larger rivals like J&J and Sanofi — framed as a competitive…
[Neutral] Novavax Acquires Praha Vaccines — Novavax acquires Praha Vaccines expanding vaccine manufacturing capacity.
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Novavax acquired Praha Vaccines on May 27, 2020 for approximately $167 million in an all-cash transaction, gaining a 150,000-square-foot vaccine and biologics manufacturing facility in Bohumil, Czech Republic (BSL-3 capable, ~150 staff). The site was intended to provide annual capacity of over 1 billion doses of antigen from 2021 for Novavax's COVID-19 vaccine candidate NVX-CoV2373 (source: Novavax IR, 2020-05-27). The large-scale manufacturing thesis never fully materialized as the vaccine's commercial launch was delayed; on December 4, 2024 Novavax agreed to sell the same Bohumil facility (and its ~300 employees) to Novo Nordisk for $200 million, expected to close by December 30, 2024, as part of a cost-reduction pivot to a leaner partnering/platform model (source: BioPharm International / FiercePharma, Dec 2024).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novavax Inc. / Praha Vaccines (this deal) | 2020 | $167M | 48 |
| Novavax Inc. / SK Bioscience Co., Ltd. | 2021 | $300M | — |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Boehringer Ingelheim International GmbH / Sanofi SA (Merial Animal Health) | 2015 | $12.4B | 81 |
| Pfizer Inc. / Baxter International Inc. (commercial vaccines portfolio) | 2014 | $635M | 77 |
| GSK plc / Affinivax Inc. | 2022 | $3.3B | 48 |
| Johnson & Johnson / Crucell N.V. | 2010 | $2.4B | 47 |
← Browse all deals · How we score deals
More: 2020 deals · Vaccines deals